



Atty. Dkt. No. 034536-1212

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Joseph SCHLESSINGER et al.

Title: NOVEL RECEPTOR-TYPE PHOSPHOTYROSINE PHOSPHATASE-
ALPHA

Appl. No.: 10/777,186

Filing Date: 02/13/2004

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/671,589, filed 09/29/2003, now U.S. Patent No. 6,682,905 B1, which is a division of application Serial No. 08/448,288, filed 05/23/1995, now U.S. Patent No. 5,88,794, which is a division of application Serial No. 08/015,985, filed 02/10/1993, now U.S. Patent No. 5,538,886, which is a continuation-in-part of application Serial No. 07/654,188, filed 02/26/1991, now abandoned, which is a continuation-in-part of application Serial No. 07/551,270, filed 07/11/1990, now abandoned. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.


Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 4/27/04

By




FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/777,186
Sheet	1	Filing Date	02/13/2004
	of 6	First Named Inventor	Joseph SCHLESSINGER
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	034536-1212



FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
	A1	WO	92/01050	A1	NEW YORK UNIVERSITY	01-23-1992
	A2	WO	94/01119	A1	NATIONAL UNIVERSITY OF SINGAPORE	01-20-1994
	A3	WO	94/03610	A2	FAMITALIA CARLO ERBA S.R.L.	02-17-1994
	A4	WO	94/09037	A1	NEW YORK UNIVERSITY MEDICAL CENTER	04-28-1994

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A5	BERGER et al., "Guide to Molecular Cloning Techniques," <u>Meth. Enzymol.</u> 152:393-399, 415-423, 432-447, 663-704 (1987)	
	A6	BUTLER et al., "Characterization of a membrane-associated phosphotyrosyl protein phosphatase from the A431 human epidermoid carcinoma cell line," <u>Eur. J. Biochem.</u> 185:475-483 (1989)	
	A7	CANNOLL et al., "The Expression of a novel receptor-type tyrosine phosphatase suggests a role in morphogenesis and plasticity of the nervous system," <u>Development Brain Research</u> , Oct. 15, 1993, pp. 293-298, vol. 75, No. 2	
	A8	CARNEY et al., "Monoclonal antibody specific for an activated RAS protein," <u>Proc. Nat. Acad. Sci. USA</u> , Oct. 1986, pp. 7485-7489, vol. 83	
	A9	CHARBONNEAU et al., "Human placenta protein-tyrosine-phosphatase: Amino acid sequence and relationship to a family of receptor-like proteins," <u>Proc. Natl. Acad. Sci. USA</u> 86:5252-5256 (1989)	
	A10	CHARBONNEAU et al., "The leukocyte common antigen (CD45): A putative receptor-linked protein tyrosine phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 85:7182-7186 (1988)	
	A11	CHERNOFF et al., "Cloning of a cDNA for a major human protein-tyrosine-phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> , 87:2735-2739 (1990)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/777,186
Filing Date	02/13/2004
First Named Inventor	Joseph SCHLESSINGER
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-1212

Sheet 2 of 6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A12	CHURCH, et al., "Genomic Sequencing", <u>Proc. Natl. Acad. Sci.</u> , vol. 81, pp. 1994-1995, (1984)	
	A13	COOL et al., "cDNA isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family," <u>Proc. Natl. Acad. Sci. USA</u> 86:5257-5261 (1989)	
	A14	COOL et al., "Overexpression of a T-cell protein tyrosine phosphatase (PTPase) in BHK Cells," <u>FASEB J.</u> 4:A2078 (abstr. 2230) (1990)	
	A15	CYERT and THORNER, "Putting it on and taking it off: Phosphoprotein phosphatase involvement in cell cycle regulation," <u>Cell</u> 57:891-893 (1989)	
	A16	DAUM et al., "Characterization of a human recombinant receptor-linked protein tyrosine phosphatase," <u>J. Biol. Chem.</u> , 266:12211-12215 (1991)	
	A17	FISCHER et al., "Protein tyrosine phosphatases: A diverse family of intracellular and transmembrane enzymes," <u>Science</u> 253:401-406 (1991)	
	A18	GEBBINK et al., "Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase," <u>FEBS Lett.</u> 290:123-130 (1991)	
	A19	GEORGE and PARKER, "Preliminary characterization of phosphotyrosine phosphatase activities in human peripheral blood lymphocytes: Identification of CD45 as a phosphotyrosine phosphatase," <u>J. Cell Biochem.</u> 42:71-81 (1990).	
	A20	GU et al., "Identification, cloning, and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1," <u>Proc. Natl. Acad. Sci. USA</u> 88:5867-5871 (1991)	
	A21	GUAN et al., "Protein Tyrosine Phosphatase Activity of an Essential Virulence Determinant in Yersinia," <u>Science</u> , Aug. 3, 1990, pp. 553-556, vol. 249.	
	A22	GUAN et al., "Cloning and expression of a protein-tyrosine-phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 87:1501-1505 (1990)	
	A23	HALL et al., "Complete exon-intron organization of the human leukocyte common antigen (CD45) gene," <u>J. Immunol.</u> 141:2781-2787 (1988)	
	A24	HARIHARAN et al., "Cloning and characterization of a receptor-class phosphotyrosine phosphatase gene expressed on central nervous system axons in Drosophila melanogaster," <u>Proc. Natl. Acad. Sci. USA</u> 88:11266-11270 (1991)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/777,186
(use as many sheets as necessary)		Filing Date	02/13/2004
		First Named Inventor	Joseph SCHLESSINGER
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	034536-1212
Sheet	3	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A25	HUNTER, "Protein-tyrosine phosphatases: The other side of the coin," <u>Cell</u> 58:1013-1016 (1989)	
	A26	JIRIK et al., "Cloning and chromosomal assignment of a widely expressed human receptor-like protein-tyrosine phosphatase," <u>FEBS Lett.</u> 273:239-242 (1990)	
	A27	JIRIK et al., "Cloning of a novel receptor-linked protein tyrosine phosphatase from a human hepatoblastoma cell line," <u>FASEB J.</u> 4A:2082 (Abstr. 2253) (1990)	
	A28	JONES et al., "Phosphotyrosyl-protein phosphatases," <u>J. Biol. Chem.</u> 264:7747-7753 (1989)	
	A29	KAPLAN et al., "Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain," <u>Proc. Natl. Acad. Sci. USA</u> 87:7000-7004 (1990)	
	A30	KIENER and MITTLER, "CD45-protein tyrosine phosphatase cross-linking inhibits T-cell receptor CD3-mediated activation in human T-cells," <u>J. Immunol.</u> 143:23-28 (1989)	
	A31	KLARLUND, "Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins," <u>Cell</u> 41:707-717 (1985)	
	A32	KRUEGER and SAITO, "A human transmembrane protein-tyrosine-phosphatase, PTP, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, pp. 7417-7421, vol. 89, No. 16.	
	A33	KRUEGER et al., "Structural diversity and evolution of human receptor-like protein tyrosine phosphatases," <u>EMBO J.</u> 9:3241-3252 (1990)	
	A34	LEVY et al., "The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system," <u>Journal of Biological Chemistry</u> , May 15, 1993, pp. 10573-10581, vol. 268, No. 14	
	A35	LOMBROSO et al., "Molecular characterization of a protein-tyrosine-phosphatase enriched in striatum," <u>Proc. Natl. Acad. Sci. USA</u> 88:7242-7246 (1991)	
	A36	MATTHEWS et al., "Characterization of hemopoietic intracellular protein tyrosine phosphatases: Description of a phosphatase containing an SH2 Domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences," <u>Molec. and Cell. Biol.</u> 12:2396-2405 (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/777,186
		Filing Date	02/13/2004
		First Named Inventor	Joseph SCHLESSINGER
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Attorney Docket Number	034536-1212		
Sheet	4	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A37	MATTHEWS et al., "Identification of an additional member of the protein-tyrosine-phosphatase family: Evidence for alternative splicing in the tyrosine phosphatase domain," <u>Proc. Natl. Acad. Sci. USA</u> 87:4444-4448 (1990)	
	A38	MUSTELIN et al., "Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 86:6302-6306 (1989)	
	A39	OHAGI et al., "Sequence of a cDNA encoding human LRP (leukocyte common antigen-related peptide)," <u>Nucl. Acids Res.</u> 18:7159 (1990)	
	A40	OSTERGAARD et al., "Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines," <u>Proc. Natl. Acad. Sci. USA</u> 86:8959-8963 (1989)	
	A41	PALLEN et al., "Purification of a phosphotyrosine phosphatase that dephosphorylates the epidermal growth factor receptor autophosphorylation sites," <u>Ann. N.Y. Acad. Sci.</u> 551:299-308 (1988)	
	A42	PINGEL and THOMAS, "Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation," <u>Cell</u> 58:1055-1065 (1989)	
	A43	PLUTZKY et al., "Isolation of a src homology 2-containing tyrosine phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 89:1123-1127 (1992)	
	A44	POT and DIXON, "A thousand and two protein tyrosine phosphatases," <u>Biochem. Biophys. Acta.</u> 1136:35-43 (1992)	
	A45	RALPH et al., "Structural variants of human T200 glycoprotein (leukocyte-common antigen)," <u>EMBO J.</u> 6:1251-1257 (1987)	
	A46	SAIKI et al., "Enzymatic amplification of .beta.-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia," <u>SCIENCE</u> , Dec. 20, 1985, pp. 1350-1354, vol. 230	
	A47	SAP et al., "Cloning and expression of a widely expressed receptor tyrosine phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 87:6112-6116 (1990)	
	A48	SCOPES, <u>Protein Purification: Principles and Practice</u> , Springer-Verlag, New York, 1987, TABLE OF CONTENTS ONLY	
	A49	SHEN et al., "A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases," <u>Nature</u> 352:736-739 (1991)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/777,186
Filing Date	02/13/2004
First Named Inventor	Joseph SCHLESSINGER
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-1212

Sheet 5 of 6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A50	STREULI et al., "A family of receptor-linked protein tyrosine phosphatases in humans and Drosophila," <u>Proc. Natl. Acad. Sci. USA</u> 86:8698-8702 (1989)	
	A51	STREULI et al., "A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen," <u>J. Exp. Med.</u> 168:1523-1530 (1988)	
	A52	STREULI et al., "Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens," <u>J. Exp. Med.</u> 166:1548-1566 (1987)	
	A53	STREULI et al., "Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases LCA and LAR," <u>EMBO Journal</u> 9:2399-2407 (1990)	
	A54	THOMAS et al., "ABA, A novel member of the tyrosine phosphatase family," <u>FASEB J.</u> 4:A2078 (Abstr. 3140) (1990)	
	A55	THOMAS, "The leukocyte common antigen family," <u>Ann. Rev. Immunol.</u> 7:339-369 (1989)	
	A56	TONKS and CHARBONNEAU, "Protein tyrosine dephosphorylation and signal transduction," <u>Trends in Biochem. Sci.</u> 14:497-500 (1989)	
	A57	TONKS et al., "CD45, an integral membrane protein tyrosine phosphatase," <u>J. Biol. Chem.</u> 265:10674-10680 (1990)	
	A58	TONKS et al., "Demonstration that the leukocyte common antigen CD45 is a protein tyrosine phosphatase," <u>Biochemistry</u> 27:8695-8701 (1988)	
	A59	TONKS et al., "Purification of the major protein-tyrosine-phosphatases of human placenta," <u>J. Biol. Chem.</u> 263:6722-6730 (1988)	
	A60	TOWBIN, et al., "Electrophoretic Transfer of Proteins From Polyacrylamide Gels To Nitrocellulose Sheets: Procedure And Some Applications", <u>Proc. Natl. Acad. Sci.</u> , vol. 76, No. 9, pp. 4350-4354, (1979)	
	A61	TSAI et al., "Isolation and characterization of temperature-sensitive and thermostable mutants of the human receptor-like protein tyrosine phosphatase LAR," <u>J. Biol. Chem.</u> 266(16):10534-10543 (1991)	
	A62	YANG and TONKS, "Isolation of a cDNA clone encoding a human protein-tyrosine phosphatase with homology to the cytoskeletal-associated proteins band 4.1, ezrin, and talin," <u>Proc. Natl. Acad. Sci. USA</u> 88:5949-5953 (1991)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information if it does not display a currently valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/777,186
Filing Date	02/13/2004
First Named Inventor	Joseph SCHLESSINGER
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-1212

Sheet	6	of	6
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

Date Considered

Examiner Signature	Considered
-----------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Enter Office that issued the document, by the two-letter code (WIPO) and the reign of the Emperor must precede the serial number of the patent document.

²See attached Kinds of U.S. Patent Documents. ³Res applicant is to place a check mark here.

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with WIPO Standard ST.3. If not, include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, if possible. ⁵ Applicant is to place a check mark here if kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Any comments on English language Translation is attached.

Time will vary depending upon the needs of the individual case. Time will vary depending upon the needs of the individual case. Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria VA 22304-1450. Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria VA 22304-1450.

*Kind of document by the appropriate symbols as indicated on the document under vvi-PO Standard ST.3). *For Japanese patent documents, please attach the Japanese original document.
 *Kind of document by the appropriate symbols as indicated on the document under vvi-PO Standard ST.3). *For Japanese patent documents, please attach the Japanese original document.
 English language Translation is attached.
 Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450